Drug Profile


Alternative Names: ASLAN003; LAS 186323

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Laboratorios Almirall
  • Developer Almirall S.A.; ASLAN Pharmaceuticals
  • Class Antirheumatics
  • Mechanism of Action Dihydroorotate dehydrogenase inhibitors; P53 gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Rheumatoid arthritis
  • Preclinical Cancer
  • Discontinued Multiple sclerosis

Most Recent Events

  • 16 Aug 2017 ASLAN Pharmaceuticals enters in to a research collaboration with Academia Sinica for Cancer
  • 01 Mar 2015 ASLAN Pharmaceuticals completes a phase I trial in Rheumatoid arthritis (In volunteers, In the elderly) in Singapore (NCT02342652)
  • 01 Aug 2013 Phase-I clinical trials in Rheumatoid arthritis (in volunteers) in Singapore (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top